Effects of repaglinide: A Synthesis of Findings from 20 Studies

  1. Home
  2. Effects of repaglinide
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of repaglinide: A Synthesis of Findings from 20 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of repaglinide: A Synthesis of Findings from 20 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Repaglinide is an effective medication for diabetes, helping to improve blood sugar control. Studies have shown that repaglinide works by stimulating insulin release in response to meals, effectively reducing postprandial hyperglycemia. 14 found that repaglinide was more effective than mitiglinide in managing high blood sugar levels caused by methylprednisolone pulse therapy. Furthermore, 17 demonstrated the efficacy of a spray drying technique to enhance the solubility of repaglinide. This technique improved the absorption and blood sugar-lowering effects of repaglinide. Additionally, 10 showed that repaglinide helps to improve postprandial hyperglycemia. These findings suggest that repaglinide is a promising drug for blood sugar management.

Benefits and Risks

Benefit Summary

Repaglinide has been shown to be effective in reducing postprandial hyperglycemia. 14 , 17 , 10

Risk Summary

Repaglinide can cause hypoglycemia. 9 It can also interact with certain enzymes and transporters such as CYP2C8 and OATP1B1. 12 , 8

Comparison of Studies

Similarities

Multiple studies have shown that repaglinide is effective in improving postprandial hyperglycemia. 14 , 17 , 10

Differences

The specific effects of repaglinide can vary depending on the patient and the administration method. 14 found that repaglinide was more effective than mitiglinide in managing high blood sugar levels caused by methylprednisolone pulse therapy. In contrast, 17 found that spray drying techniques enhanced the solubility and blood sugar-lowering effects of repaglinide. 10 showed that repaglinide helped to improve postprandial hyperglycemia. These studies suggest that the effects of repaglinide may vary depending on the patient and the administration method.

Consistency and Contradictions of Results

Multiple studies have shown that repaglinide is effective in improving postprandial hyperglycemia. However, the specific effects of repaglinide can vary depending on the patient and the administration method. 14 , 17 , 10

Points to Consider in Real-Life Applications

While repaglinide effectively lowers blood sugar levels after meals, it’s important to be aware of the potential for hypoglycemia. 9 Furthermore, repaglinide can interact with other medications, so consulting a doctor and following their instructions for taking the drug is crucial. 12 , 8

Limitations of Current Research

There is still limited research on repaglinide. More research is needed to evaluate its long-term effects and safety.

Future Research Directions

Further research is necessary to understand the long-term effects and safety of repaglinide. Additionally, research is needed to determine the optimal dosage and interaction with other medications.

Conclusion

Numerous studies have demonstrated that repaglinide is effective in improving postprandial hyperglycemia. However, it is crucial to be aware of its potential to cause hypoglycemia. 9 Moreover, interactions with other medications are possible, highlighting the importance of consulting a physician and following their instructions for taking repaglinide. 12 , 8 While more research is needed on repaglinide, current evidence suggests that it is a valuable tool for managing blood sugar levels.

Literature analysis of 20 papers
Positive Content
17
Neutral Content
3
Negative Content
0
Article Type
5
1
1
0
20
1.

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

Author: WolffenbuttelB H, NijstL, SelsJ P, MenheereP P, MüllerP G, KrusemanA C

Diabetes treatment
Repaglinide effective

Repaglinide, a new oral hypoglycaemic agent, effectively lowered postprandial blood glucose levels in patients with NIDDM. In a study of 44 patients, repaglinide was more effective than glibenclamide in reducing postprandial blood glucose. Both drugs reduced total cholesterol levels. Repaglinide was well-tolerated with no significant side effects observed.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.

Author: NiemiM, NeuvonenP J, KivistöK T

Lower blood glucose
Hypoglycemia

Clarithromycin was found to increase the plasma concentrations and effects of repaglinide. Clarithromycin increased the area under the concentration-time curve of repaglinide by 40% and the peak plasma concentration by 67%. Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.

Author: KajosaariLauri I, BackmanJanne T, NeuvonenMikko, LaitilaJouko, NeuvonenPertti J

Lower blood glucose

Gemfibrozil is a drug that lowers cholesterol and increases the effects of the diabetes drug repaglinide. This study will examine the effects of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Effects of in vitro repaglinide supplementation on improving sperm motility parameters, viability, and DNA integrity in normozoospermic and asthenozoospermic men.

Author: KalehoeiEshrat, AzadbakhtMehri, KarimiNazanin, NowrouziFatemeh, JalilianNasrin, KeshavarziFarahnaz

This study examined the effects of repaglinide, an antidiabetic drug, on human sperm motility, viability, and DNA integrity in normozoospermic and asthenozoospermic men.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Clinical Effects of Exercise Rehabilitation Combined with Repaglinide in the Treatment of Diabetes.

Author: LiYan, WangXi, ZhangYing

Blood glucose improvement

This study explored the clinical effects of repaglinide combined with exercise rehabilitation on improving blood glucose in patients with diabetes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

8.

Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis.

Author: ZhouShuang, XiangQian, MuGuangyan, MaLingyue, ChenShuqing, XieQiufen, ZhangZhuo, CuiYimin

repaglinide pharmacokinetics
limited data

The genotype of CYP2C8, but not SLCO1B1, may affect repaglinide pharmacokinetics. More studies are needed to confirm these findings.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

11.

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.

Author: WangJing, ZhangZhi-Yi, LuSharon, PowersDan, KansraVikram, WangXiaodong

CYP interactions

Rolapitant is a neurokinin-1 receptor antagonist that prevents delayed chemotherapy-induced nausea and vomiting. This study investigated the effects of rolapitant on the pharmacokinetics of several cytochrome P450 (CYP) substrates in healthy individuals.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

12.

Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.

Author: PeiQi, LiuJun-Yan, YinJi-Ye, YangGuo-Ping, LiuShi-Kun, ZhengYi, XiePan, GuoCheng-Xian, LuoMi, ZhouHong-Hao, LiXi, LiuZhao-Qian

Drug interaction

The study investigated the impact of angiotensin II receptor blockers (ARBs) on the pharmacokinetics (PK) and pharmacodynamics (PD) of repaglinide in Chinese healthy volunteers with different SLCO1B1 genotypes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

13.

Characteristics of repaglinide effects on insulin secretion.

Author: TakahashiHarumi, HidakaShihomi, SekiChihiro, YokoiNorihide, SeinoSusumu

GLP-1 combination effectiveness
Insulin secretion stimulation

Repaglinide, a glinide, induced insulin secretion with different dynamics compared to glimepiride, a sulfonylurea.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

14.

The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy.

Author: TanakaKenichi, OkadaYosuke, MoriHiroko, TorimotoKeiichi, AraoTadashi, TanakaYoshiya

Steroid-induced diabetes

Methylprednisolone (MP) pulse therapy can lead to an acute dose-dependent increase in blood glucose levels. All 5 patients in this study developed steroid-induced diabetes. Repaglinide was more effective than mitiglinide in managing glucose levels before lunch and dinner.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

16.

Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.

Author: YamazakiTakao, DesaiAmit, GoldwaterRonald, HanDavid, HowiesonCorrie, AkhtarShahzad, KowalskiDonna, LademacherChristopher, PearlmanHelene, RammelsbergDiane, TownsendRobert

Drug interactions

This phase 1 study assessed interactions of oral isavuconazole with single oral doses of cytochrome P450 (CYP) substrates. The study found that isavuconazole is a mild inducer of CYP2B6 but does not appear to affect CYP1A2-, CYP2C8-, or CYP2D6-mediated metabolism.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

18.

Comparative Study of the Antioxidant Effects of Metformin, Glibenclamide, and Repaglinide in Alloxan-Induced Diabetic Rats.

Author: Chukwunonso ObiBonaventure, Chinwuba OkoyeTheophine, OkpashiVictor Eshu, Nonye IgweChristiana, Olisah AlumanahEdwin

Improved antioxidant enzymes
Reduced oxidative stress

Metformin, glibenclamide, and repaglinide, standard diabetes medications, were found to exhibit antioxidant effects in alloxan-induced diabetic rats, potentially contributing to the protection against oxidative stress-related complications.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

19.

Effects of nateglinide and repaglinide administered intracerebroventricularly on the CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice.

Author: KimChea-Ha, ParkSoo-Hyun, SimYun-Beom, KimSung-Su, KimSu-Jin, LimSu-Min, JungJun-Sub, SuhHong-Won

Neuroprotection

Repaglinide, but not nateglinide, when administered supraspinally, demonstrated a protective effect against kainic acid-induced neuronal cell death in the hippocampus of mice. This protection appears to be mediated by repaglinide's ability to lower blood glucose levels.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

Effects of NOS1AP rs12742393 polymorphism on repaglinide response in Chinese patients with type 2 diabetes mellitus.

Author: WangTao, WangYan, LvDong-Mei, SongJin-Fang, LuQian, GaoXing, ZhangFan, GuoHao, LiWei, YinXiao-Xing

NOS1AP variant affects repaglinide efficacy

The NOS1AP rs12742393 polymorphism was found to be associated with therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes mellitus (T2DM).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.